Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ACENOCOUMAROL”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources
PubMed1981

[The effect of sulfinpyrazone on the coagulation-inhibiting action of acenocoumarol].

To investigate the possible clinical interaction between the platelet function regulator sulphinpyrazone (SP) and the oral anticoagulant acenocoumarol (AC), 22 in-patients of either sex were included in a single blind within-patient trial vs. placebo. After one week of stabilizing treatment with AC alone the patients were randomly allocated to two sequences (11 patients each), either SP + AC for weeks 2--3 followed by placebo + AC for weeks 4--5, or the reverse sequence, i.e. placebo + AC followed by SP + AC for the same periods. 17 patients completed the full five weeks. Four dropped out during SP treatment, all but one following some form of bleeding episode. One patient dropped out for the same reason during placebo. Apart from the bleeding episodes, no other undesirable effects were recorded. The daily dose of SP was always 800 mg. A statistically highly significant interaction (p less than 0.01) between SP and AC was found. The addition of SP to AC led to a drop in mean prothrombin time and rendered necessary a consequent reduction (of about 20%) in mean AC dosage. It is concluded that when initiating and withdrawing treatment with SP in a patient receiving AC, the prothrombin time should be checked daily for a few days to adapt (reduce) the dosage of AC to the change in prothrombin time induced by SP.

Acenocoumarol↗
PubMed1995

Retroperitoneal haematoma in a patient treated with acenocoumarol, phenytoin and paroxetine.

Coumarin anticoagulants must be strictly monitored because of their narrow therapeutic index and their potential interactions with other drugs. The high probability of interactions can be explained by two pharmacokinetic properties of coumarins: high binding to plasma albumin (99%), being displaced by other drugs with greater affinity to this protein, and metabolism by liver microsomal enzymes (cytochrome P450), which can be induced or inhibited by other compounds (Shinn & Shrewsbury 1985). A case is reported of a clinically relevant drug interaction of phenytoin and acenocoumarol, possibly potentiated by concomitant treatment with paroxetine, leading to a retroperitoneal haematoma.

Acenocoumarol↗
PubMedDate not supplied

[A study of the incidence and hospital follow-up of epistaxis in patients treated with anticoagulant acenocoumarol].

Nosebleed is a common reason for emergency ENT consultations, but it is infrequent in patients anticoagulated with acenocoumarol. In a retrospective 5-year study, nosebleed was the second most frequent type of hemorrhage among anticoagulated patients. Such patients do not necessarily have prolonged coagulation times. In a comparison of patients hospitalized for nosebleed (n = 14) with a similar group with no hemostasis abnormalities, patients with nosebleed had longer hospital stays and required more control measures. The greater the tendency to hypocoagulation, the more difficult it was to manage nosebleed. Recent onset of anticoagulation therapy and previous long coagulation times favored the appearance of hard-to-manage nosebleed. Therefore, hematologists should closely control patients under anticoagulation therapy and cooperate with the ENT department when such patients are admitted for nosebleed.

Acenocoumarol↗
PubMed1998

Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol.

This study establishes a population PK model for FVII clotting activity (FVII:C) after injection of recombinant activated factor VII (rFVIIa) to healthy volunteers. Twenty eight volunteers, anticoagulated with acenocoumarol, received one or two rFVIIa injections, with dose ranging from 5 to 320 microg/kg. The FVII:C kinetic was fitted to a 2 compartment model, with continuous "endogenous perfusion" mimicking endogenous activity. Estimated clearance was 2.4 1/h (20% inter-individual variability and 9% inter-period variability). The volume of distribution at steady-state appeared to be significantly dose dependent: 78 ml/kg for doses < or = 20 microg/kg and 88 ml/kg for doses > 20 microg/kg respectively, with 16% inter-individual variability. The dose producing 50% of the maximum drop of INR was estimated to be 2.2 microg/kg. The model will be used to better define the dosage regimen for future clinical developments.

Acenocoumarol↗
PubMed1998

[Upper airway obstruction as a complication of acenocoumarol treatment].

The case-histories of three patients treated with acenocumarol attended urgently because of sudden onset dyspnea and dysphonia an presented. Endoscopic and radiologic studies revealed in these patients a laryngeal obstruction by haematomas in a different grade, due to an excess in the effect of anticoagulant therapy, since prothrombine times measured as INR were too high. In one of the cases, the sudden and infrequent evolution associating initialy difficulty of breathing without any inspiratory or phonetic disorder, moved to a late diagnosis with a tragic ending, because it delayed an urgent tracheostomy, which bled profusely. It was a patient with a defective anticoagulant therapy control and numerous previous haemorrhagic incidents. The not so fulminant pattern in the other two cases allowed its early diagnostic and treatment planning, which included the admission to hospital and withdrawal of the anticoagulant drug and the vigilance of symptoms, up to confirm healing. Haemorrhagic laryngeal complications due to acenocoumarol, though unusual, imply an obvious vital trouble that moves to an urgent therapeutic attitude more or less aggressive. Its clinical suspicion obliges to its early discard.

Acenocoumarol↗